Vir Biotechnology, Inc. – NASDAQ:VIR

Add to watchlist

$4.35

-3.12

-41.77%

Market closed

Open in 3 days

-20.28%

month

-20.28%

quarter

-26.91%

year

Market Cap	1.02B
Enterprise value	2.39B

P/E	5.98
EV/Sales	1.48
EV/EBITDA	3.10
Price/Sales	1.92
Price/Book	1.50
PEG ratio	-0.48
EPS	-4.01

Revenue	56.34M
EBITDA	-554.72M
Income	-539.43M
Revenue Q/Q	20.68%
Revenue Y/Y	-85.81%

Profit margin	31.92%
Oper. margin	51.56%
Gross margin	90.94%
EBIT margin	51.56%
EBITDA margin	-984.55%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Vir Biotechnology, Inc. (NASDAQ:VIR): Profit margin
Jun 2023	-12.72M	-194.77M	1531.01%
Sep 2023	-4.09M	-163.41M	3987.63%
Dec 2023	16.78M	-115.97M	-690.85%
Mar 2024	56.37M	-65.27M	-115.79%

Vir Biotechnology Financials Estimate

Q Y

Vir Biotechnology, Inc. (NASDAQ:VIR): Analyst Estimates
Mar 2024	56.37M	-65.27M	-115.79%
Sep 2025	18.4M	-150.76M	-819.36%
Oct 2025	18.4M	-129.86M	-705.81%
Dec 2025	18.4M	-78.46M	-426.43%

Analysts Price target
Financials & Ratios estimates

Vir Biotechnology, Inc. (NASDAQ:VIR): Debt to assets
Jun 2023	2243874000	433.66M	19.33%
Sep 2023	2044895000	369.81M	18.08%
Dec 2023	1960090000	369.85M	18.87%
Mar 2024	1793969000	246.61M	13.75%

Vir Biotechnology, Inc. (NASDAQ:VIR): Cash Flow
Jun 2023	-389.24M	230.31M	3.17M
Sep 2023	-155.82M	-58.95M	277K
Dec 2023	-107.92M	-104.81M	1.68M
Mar 2024	-109.39M	28.42M	152K

Vir Biotechnology alternative data

Vir Biotechnology, Inc. (NASDAQ:VIR): Employee count
Aug 2023	576
Sep 2023	576
Oct 2023	576
Nov 2023	576
Dec 2023	576
Jan 2024	576
Feb 2024	576
Mar 2024	587
Apr 2024	587
May 2024	587
Jun 2024	587
Jul 2024	587

Vir Biotechnology
Hedge Funds Holdings Q3 2022

57.90% -5.69%

of VIR is owned by hedge funds

196 -8

hedge funds hold VIR stock

76.69M -8.85M

shares is hold by hedge funds

VIR hedge funds holdings changes

Vir Biotechnology
Insider Trading

Vir Biotechnology, Inc. (NASDAQ:VIR): Insider trades (number of shares)
Period	Buy	Sel
Feb 2024	0	85685
Mar 2024	0	6008
Apr 2024	0	75706
Jun 2024	0	4000
Sep 2024	0	12190
Nov 2024	0	8147
Dec 2024	0	76

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	2 Dec 2024	DE VERNEUIL VANINA officer: EVP and General Counsel officer: EVP and General Counsel	Common Stock	76	$8.22	$625
Sale	6 Nov 2024	DE VERNEUIL VANINA officer: EVP and General Counsel officer: EVP and General Counsel	Common Stock	4,397	$10.11	$44,454
Sale	5 Nov 2024	DE VERNEUIL VANINA officer: EVP and General Counsel officer: EVP and General Counsel	Common Stock	2,347	$9.47	$22,226
Sale	1 Nov 2024	DE VERNEUIL VANINA officer: EVP and General Counsel officer: EVP and General Counsel	Common Stock	1,403	$7.2	$10,107
Sale	9 Sep 2024	NAPOLITANO JANET director director	Common Stock	12,190	$7.8	$95,033
Sale	11 Jun 2024	RAMASASTRY SAIRA director director	Common Stock	4,000	$10.95	$43,788
Sale	3 Apr 2024	DE BACKER MARIANNE director, officer: Chief Executive Offi.. director, officer: Chief Execut..	Common Stock	72,995	$9.46	$690,387
Sale	1 Apr 2024	HANLY ANN M. officer: EVP & Chief Technology Officer officer: EVP & Chief Technology..	Common Stock	2,711	$10.05	$27,251
Sale	27 Mar 2024	LEE SUNG officer: EVP & Chief Financial Officer officer: EVP & Chief Financial ..	Common Stock	6,008	$9.89	$59,407
Sale	26 Feb 2024	SCANGOS GEORGE A director	Common Stock	17,722	$11.65	$206,514

VIR insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application CORONAVIRUS IRNA COMPOSITIONS AND METHODS OF USE THEREOF Filling date: 10 Nov 2021 Issue date: 28 Apr 2022	10 Nov 2021	28 Apr 2022
Application	Application COMBINATION HBV THERAPY Filling date: 19 Dec 2019 Issue date: 24 Feb 2022	19 Dec 2019	24 Feb 2022
Application	Application ENGINEERED MICROORGANISMS AND METHODS OF MAKING AND USING SAME Filling date: 20 Sep 2019 Issue date: 3 Feb 2022	20 Sep 2019	3 Feb 2022
Application	Application ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF USING THE SAME Filling date: 23 Jul 2021 Issue date: 2 Dec 2021	23 Jul 2021	2 Dec 2021
Grant	Grant Utility: Antibodies against SARS-CoV-2 and methods of using the same Filling date: 25 Feb 2021 Issue date: 9 Nov 2021	25 Feb 2021	9 Nov 2021
Application	Application ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF USING THE SAME Filling date: 25 Feb 2021 Issue date: 26 Aug 2021	25 Feb 2021	26 Aug 2021
Application	Application HIV VACCINES COMPRISING ONE OR MORE POPULATION EPISENSUS ANTIGENS Filling date: 31 Aug 2020 Issue date: 18 Feb 2021	31 Aug 2020	18 Feb 2021
Application	Application HIV VACCINES COMPRISING ONE OR MORE POPULATION EPISENSUS ANTIGENS Filling date: 31 Aug 2020 Issue date: 18 Feb 2021	31 Aug 2020	18 Feb 2021
Grant	Grant Utility: HIV vaccines comprising one or more population episensus antigens Filling date: 5 Oct 2015 Issue date: 19 Jan 2021	5 Oct 2015	19 Jan 2021

Vir Biotechnology
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 3 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 22 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 2 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 3 Aug 2023	Q2 2023 Earnings Call Transcript

VIR earnings call transcripts

Vir Biotechnology
Executives

Insider	Age	Compensation
Dr. Herbert W. Virgin IV (1956) Executive Vice President of Research & Chief Scientific Officer	69	$1,110,000
Dr. George A. Scangos (1948) Pres, Chief Executive Officer & Director	77	$994,880
Mr. Steven J. Rice (1960) Chief Admin. Officer	65	$698,620
Mr. Howard Horn (1978) Chief Financial Officer & Sec.	47	$681,830

Vir Biotechnology
Latest News

Wednesday, 18 December 2024
09:30	Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference	businesswire.com
Friday, 13 December 2024
12:57	Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January	seekingalpha.com
Thursday, 12 December 2024
16:05	Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta	businesswire.com
Tuesday, 26 November 2024
09:30	Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs	businesswire.com
Monday, 25 November 2024
09:30	Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference	businesswire.com
Monday, 18 November 2024
21:15	Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program	businesswire.com
16:05	Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency	businesswire.com
Friday, 15 November 2024
11:00	Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting	businesswire.com
Tuesday, 5 November 2024
11:29	Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off	seekingalpha.com
Thursday, 31 October 2024
23:12	Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript	seekingalpha.com
18:20	Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates	zacks.com
Thursday, 17 October 2024
16:30	Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024	businesswire.com
Thursday, 3 October 2024
16:00	Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference	businesswire.com
Tuesday, 6 August 2024
10:55	Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High?	zacks.com
09:15	Prediction: This Pharma Stock Will Be the Best Performer the Rest of 2024	247wallst.com
Thursday, 1 August 2024
22:10	Vir Biotechnology, Inc. (VIR) Q2 2024 Earnings Call Transcript	seekingalpha.com
18:51	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates	zacks.com
16:02	Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities	businesswire.com
Thursday, 18 July 2024
16:05	Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024	businesswire.com
Wednesday, 17 July 2024
16:47	Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis	seekingalpha.com
Thursday, 4 July 2024
10:01	3 Undervalued Biotech Gems With 200%+ Analyst Price Targets	investorplace.com
Wednesday, 26 June 2024
08:05	Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection	businesswire.com
Thursday, 6 June 2024
14:31	Vir Biotechnology (VIR) Up on Positive Data From HDV Study	zacks.com
Wednesday, 5 June 2024
05:30	Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment	businesswire.com
Wednesday, 29 May 2024
16:05	Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	businesswire.com
08:05	Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer	businesswire.com
Thursday, 23 May 2024
16:05	Vir Biotechnology to Host 2024 Annual Meeting of Stockholders	businesswire.com
Wednesday, 22 May 2024
08:05	Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024	businesswire.com
08:00	Reser's Fine Foods Kicks Off 2024 ‘Good Times Tour'	businesswire.com
Tuesday, 21 May 2024
08:17	Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024	businesswire.com

Ideas & Opinions

Seeking Alpha 23 Jul 2025

Vir Biotechnology: Hep B And Cancer Projects March On
Seeking Alpha 8 May 2025

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment
Seeking Alpha 13 Jan 2025

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
Seeking Alpha 9 Jan 2025

Vir Biotechnology: A Rocket Off Phase 1 Data... What Could Go Wrong?
Seeking Alpha 13 Dec 2024

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January
Seeking Alpha 6 Jun 2024

Fulgent Genetics: Growth Is Returning
Seeking Alpha 8 Nov 2023

Vir Biotechnology: A Relentless Slide In The Stock, Unresponsive To Positive Developments
Seeking Alpha 19 Oct 2023

Vir Biotechnology: A Beaten Up Biotech With A Large Margin Of Safety
Seeking Alpha 27 Jul 2023

Intellia Therapeutics: The Future Is Here
Seeking Alpha 17 May 2023

Arbutus: Two Data Readouts Of AB-729 Could Shift Momentum In 2023

Frequently Asked Questions (FAQ)

What's the price of Vir Biotechnology stock today?

One share of Vir Biotechnology stock can currently be purchased for approximately $4.35.
When is Vir Biotechnology's next earnings date?

Unfortunately, Vir Biotechnology's (VIR) next earnings date is currently unknown.
Does Vir Biotechnology pay dividends?

No, Vir Biotechnology does not pay dividends.
How much money does Vir Biotechnology make?

Vir Biotechnology has a market capitalization of 1.02B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 94.55% to 86.18M US dollars.
What is Vir Biotechnology's stock symbol?

Vir Biotechnology, Inc. is traded on the NASDAQ under the ticker symbol "VIR".
What is Vir Biotechnology's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Vir Biotechnology?

Shares of Vir Biotechnology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Vir Biotechnology's key executives?
Vir Biotechnology's management team includes the following people:
- Dr. Herbert W. Virgin IV Executive Vice President of Research & Chief Scientific Officer(age: 69, pay: $1,110,000)
- Dr. George A. Scangos Pres, Chief Executive Officer & Director(age: 77, pay: $994,880)
- Mr. Steven J. Rice Chief Admin. Officer(age: 65, pay: $698,620)
- Mr. Howard Horn Chief Financial Officer & Sec.(age: 47, pay: $681,830)
How many employees does Vir Biotechnology have?

As Jul 2024, Vir Biotechnology employs 587 workers.
When Vir Biotechnology went public?

Vir Biotechnology, Inc. is publicly traded company for more then 5 years since IPO on 11 Oct 2019.
What is Vir Biotechnology's official website?

The official website for Vir Biotechnology is vir.bio.
Where are Vir Biotechnology's headquarters?

Vir Biotechnology is headquartered at 499 Illinois Street, San Francisco, CA.
How can i contact Vir Biotechnology?

Vir Biotechnology's mailing address is 499 Illinois Street, San Francisco, CA and company can be reached via phone at +41 59064324.

Vir Biotechnology, Inc.

vir.bio

Exchange:

NASDAQ

Full time employees:

587

Industry:

Biotechnology

Sector:

Healthcare

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

+41 59064324

499 Illinois Street
San Francisco, CA 94158

CIK: 0001706431
ISIN: US92764N1028
CUSIP: 92764N102